- Home
- PHAR vs NFE Comparison
PHAR vs NFE Comparison
Compare PHAR & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NFE
- Stock Information
- Founded
- PHAR 1988
- NFE 2014
- Country
- PHAR Netherlands
- NFE United States
- Employees
- PHAR N/A
- NFE N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NFE Oil/Gas Transmission
- Sector
- PHAR Health Care
- NFE Utilities
- Exchange
- PHAR Nasdaq
- NFE Nasdaq
- Market Cap
- PHAR 951.7M
- NFE 773.2M
- IPO Year
- PHAR N/A
- NFE 2019
- Fundamental
- Price
- PHAR $14.34
- NFE $2.12
- Analyst Decision
- PHAR Strong Buy
- NFE Strong Buy
- Analyst Count
- PHAR 3
- NFE 5
- Target Price
- PHAR $30.00
- NFE $7.70
- AVG Volume (30 Days)
- PHAR 14.9K
- NFE 28.8M
- Earning Date
- PHAR 10-23-2025
- NFE 11-06-2025
- Dividend Yield
- PHAR N/A
- NFE N/A
- EPS Growth
- PHAR N/A
- NFE N/A
- EPS
- PHAR N/A
- NFE N/A
- Revenue
- PHAR $339,836,000.00
- NFE $2,006,240,000.00
- Revenue This Year
- PHAR $17.44
- NFE $10.40
- Revenue Next Year
- PHAR $8.46
- NFE $11.08
- P/E Ratio
- PHAR N/A
- NFE N/A
- Revenue Growth
- PHAR 22.44
- NFE N/A
- 52 Week Low
- PHAR $7.31
- NFE $1.26
- 52 Week High
- PHAR $17.08
- NFE $16.66
- Technical
- Relative Strength Index (RSI)
- PHAR 50.39
- NFE 45.01
- Support Level
- PHAR $14.22
- NFE $2.10
- Resistance Level
- PHAR $16.29
- NFE $2.66
- Average True Range (ATR)
- PHAR 0.50
- NFE 0.29
- MACD
- PHAR -0.13
- NFE 0.02
- Stochastic Oscillator
- PHAR 37.30
- NFE 15.05
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.